<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958773</url>
  </required_header>
  <id_info>
    <org_study_id>CP 17-01</org_study_id>
    <nct_id>NCT03958773</nct_id>
  </id_info>
  <brief_title>Cardiovalve Transfemoral System - FIM Study</brief_title>
  <official_title>Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk With Severe Mitral Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovalve Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiovalve Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cardiovalve system is a replacement valve delivered through a transfemoral access and&#xD;
      transseptal approach and is intended for symptomatic patients with Mitral regurgitation for&#xD;
      whom surgical options are not feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Cardiovalve system is a replacement valve delivered through a transfemoral access and&#xD;
      transseptal approach and is intended for symptomatic patients with Mitral regurgitation for&#xD;
      whom surgical options are not feasible.&#xD;
&#xD;
      The purpose of this study is to evaluate the safety of the CardiovalveSystem with its&#xD;
      associated procedure, and observe the device performance in reducing mitral regurgitation&#xD;
      Data collected in this clinical study will include 30-day safety and performance of the&#xD;
      device and delivery system, and long-term clinical outcomes over a follow-up of 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-center, single-arm feasibility clinical study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from major device or procedure related serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from major device or procedure related serious adverse events:&#xD;
F. Stage 2 or 3 acute kidney injury (includes new dialysis) H. Severe hypotension, worsening of heart failure, or respiratory failure requiring intravenous pressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for &gt;48 h.&#xD;
I. Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Technical success; delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging Number of patients for whom the device was successfully implanted (per MVARC definitions) Number of patients with reduction in MR grade from Baseline Number of patients with improvement in NYHA class from baseline Number of patients with increase distance walked in the 6MW test from baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Cardiovalve treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that implanted with the Cardiovalve device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiovalve transfemoral Mitral valve system</intervention_name>
    <description>Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.</description>
    <arm_group_label>Cardiovalve treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  NYHA functional II, III or ambulatory IV&#xD;
&#xD;
          -  Severe mitral regurgitation (MR grade 3-4+)&#xD;
&#xD;
          -  High risk for conventional open mitral valve repair or replacement surgery in the&#xD;
             consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and&#xD;
             imaging specialist as a minimum)&#xD;
&#xD;
          -  Able to undergo Transesophageal Echocardiography (TEE).&#xD;
&#xD;
          -  Subject understands the study requirements and the treatment procedures and provides&#xD;
             written Informed Consent before any study-specific tests or procedures are performed.&#xD;
&#xD;
          -  The subject commits to return for the scheduled post-operative follow-up visits at the&#xD;
             hospital.&#xD;
&#xD;
          -  Suitable for femoral access procedure and transseptal catheterization&#xD;
&#xD;
          -  Native mitral valve geometry and size and LV outflow tract characteristics compatible&#xD;
             with the Cardiovalve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior stroke or TIA within 3 months&#xD;
&#xD;
          -  Acute myocardial infarction within the previous 30 days&#xD;
&#xD;
          -  Any prior heart valve surgery or transcatheter mitral intervention&#xD;
&#xD;
          -  Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid&#xD;
             surgery within 30 days&#xD;
&#xD;
          -  Rheumatic heart disease or endocarditis within the previous 3 months&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          -  Existence of inferior vena cava filter or atrial septal device (contraindicating&#xD;
             femoral access and transseptal catheterization)&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          -  Tricuspid valve disease requiring surgery or severe tricuspid regurgitation&#xD;
&#xD;
          -  Aortic valve disease requiring surgery Anatomical Exclusion Criteria (assessed by&#xD;
             pre-procedural imaging)&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction ( LVEF) &lt;30%&#xD;
&#xD;
          -  LV end diastolic diameter &gt; 70mm&#xD;
&#xD;
          -  Significant abnormalities of the mitral valve and sub-valvular apparatus.&#xD;
&#xD;
          -  Severe mitral annular or leaflets calcification&#xD;
&#xD;
          -  Left atrial or LV thrombus&#xD;
&#xD;
          -  Severe right ventricular dysfunction&#xD;
&#xD;
          -  Severe tricuspid or aortic valve disease General Exclusion Criteria&#xD;
&#xD;
          -  Subject who is currently participating in an investigational study, other than this&#xD;
             study&#xD;
&#xD;
          -  Hemodynamic instability defined as systolic pressure &lt; 90mmHg or the need for&#xD;
             inotropic support or intra-aortic balloon pump or other hemodynamic support device, or&#xD;
             any mechanical heart assistance&#xD;
&#xD;
          -  Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated,&#xD;
             has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to&#xD;
             antiplatelet, anticoagulant, or thrombolytic medications&#xD;
&#xD;
          -  Bleeding diathesis or hypercoagulable state&#xD;
&#xD;
          -  Active peptic ulcer or active gastrointestinal bleeding&#xD;
&#xD;
          -  Pulmonary artery systolic pressure &gt;70 mmHg&#xD;
&#xD;
          -  Patients with renal insufficiency (creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
          -  Subject with hepatic insufficiency&#xD;
&#xD;
          -  Subject has a co-morbid illness that may result in a life expectancy of less than one&#xD;
             year&#xD;
&#xD;
          -  Active infection that requires antibiotic therapy&#xD;
&#xD;
          -  Subject is pregnant, breastfeeding or intend to become pregnant within one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rimantas Benetis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nitza Shoham, PhD</last_name>
    <phone>+972765388142</phone>
    <phone_ext>8142</phone_ext>
    <email>nitza@cardiovalve.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronit Pick</last_name>
    <email>ronit@cardiovalve.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the Lithuanian University of Health Sciences ligoninÄ— Kauno</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimantas Benetis, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2019</study_first_submitted>
  <study_first_submitted_qc>May 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve</keyword>
  <keyword>Functional mitral regurgitation</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

